RxLogix is excited to announce the expansion of our relationship with one of the fastest growing biotech, focused on the creation and development of innovative and differentiated antibody products, with the aim of improving the lives of cancer patients.

In the month of July RxLogix successfully took our client live on Argus J. It will enable the client’s Japan teams to use the Global Drug Safety Platform for Japanese drug safety and reporting requirements.

This is in addition to the deployment of the Global Argus Safety platform, + PV Repots + PV Central which we already host and maintain for this client.

In this project, the team has accomplished following strategic benefits:

• Improved governance and visibility of client’s safety data.
• Audit/inspection readiness.
• Improved flexibility and scalability to expand geographically.
• Extend the use of best-in-class, Argus drug safety system to the client’s Japan team.